The phase 3 TH3RESA trial compared the efficacy of T-DM1 with the physician’s choice of treatment in patients with HER2-positive advanced breast cancer previously treated and with progression after at least two HER2-directed regimens. Here, ERBB2 is linked to breast carcinoma.